CN1279040C - 用于治疗的莨菪烷衍生物 - Google Patents

用于治疗的莨菪烷衍生物 Download PDF

Info

Publication number
CN1279040C
CN1279040C CNB018088287A CN01808828A CN1279040C CN 1279040 C CN1279040 C CN 1279040C CN B018088287 A CNB018088287 A CN B018088287A CN 01808828 A CN01808828 A CN 01808828A CN 1279040 C CN1279040 C CN 1279040C
Authority
CN
China
Prior art keywords
formula
compound
pharmaceutically acceptable
preparation
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018088287A
Other languages
English (en)
Chinese (zh)
Other versions
CN1437599A (zh
Inventor
M·派洛斯
D·A·普利斯
B·L·C·司塔曼
A·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CN1437599A publication Critical patent/CN1437599A/zh
Application granted granted Critical
Publication of CN1279040C publication Critical patent/CN1279040C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
CNB018088287A 2000-05-26 2001-05-09 用于治疗的莨菪烷衍生物 Expired - Lifetime CN1279040C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0014046.7 2000-05-26
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
GB0015835.2 2000-06-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2006100735840A Division CN1830445B (zh) 2000-05-26 2001-05-09 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物
CNB2005100068151A Division CN100355753C (zh) 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体

Publications (2)

Publication Number Publication Date
CN1437599A CN1437599A (zh) 2003-08-20
CN1279040C true CN1279040C (zh) 2006-10-11

Family

ID=26244452

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018088287A Expired - Lifetime CN1279040C (zh) 2000-05-26 2001-05-09 用于治疗的莨菪烷衍生物
CNB2005100068151A Expired - Lifetime CN100355753C (zh) 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100068151A Expired - Lifetime CN100355753C (zh) 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体

Country Status (50)

Country Link
EP (3) EP1990341B1 (enExample)
JP (2) JP3693957B2 (enExample)
KR (2) KR100523501B1 (enExample)
CN (2) CN1279040C (enExample)
AP (1) AP1965A (enExample)
AR (2) AR028622A1 (enExample)
AT (2) ATE407134T1 (enExample)
AU (2) AU5248201A (enExample)
BG (1) BG65966B1 (enExample)
BR (1) BRPI0110955B8 (enExample)
CA (1) CA2408909C (enExample)
CR (1) CR10145A (enExample)
CU (1) CU23288B7 (enExample)
CY (3) CY2008006I1 (enExample)
CZ (1) CZ299102B6 (enExample)
DE (3) DE122008000011I1 (enExample)
DK (2) DK1526134T3 (enExample)
DZ (1) DZ3464A1 (enExample)
EA (2) EA007580B1 (enExample)
EE (1) EE05110B1 (enExample)
EG (1) EG24137A (enExample)
ES (3) ES2311126T3 (enExample)
FR (1) FR08C0007I2 (enExample)
GE (1) GEP20063799B (enExample)
HR (1) HRP20020938B1 (enExample)
HU (1) HU225810B1 (enExample)
IL (2) IL152531A0 (enExample)
IS (1) IS2511B (enExample)
LT (1) LTC1284974I2 (enExample)
LU (1) LU91417I2 (enExample)
MA (1) MA26902A1 (enExample)
ME (1) ME00555B (enExample)
MX (1) MXPA02011631A (enExample)
MY (3) MY156920A (enExample)
NL (1) NL300338I2 (enExample)
NO (3) NO327892B1 (enExample)
NZ (1) NZ521477A (enExample)
OA (1) OA12264A (enExample)
PA (1) PA8517101A1 (enExample)
PE (1) PE20011371A1 (enExample)
PL (1) PL200551B1 (enExample)
PT (2) PT1526134E (enExample)
RS (2) RS50904B (enExample)
SI (2) SI1526134T1 (enExample)
SK (1) SK286129B6 (enExample)
TN (1) TNSN01077A1 (enExample)
TR (1) TR200400541T4 (enExample)
TW (1) TWI230160B (enExample)
UY (1) UY26727A1 (enExample)
WO (1) WO2001090106A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693957B2 (ja) * 2000-05-26 2005-09-14 ファイザー・インク 療法において有用なトロパン誘導体
WO2002100848A1 (en) * 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
EA007590B1 (ru) * 2002-04-08 2006-12-29 Пфайзер Инк. Производные тропана в качестве модуляторов ccr5
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
MXPA04011577A (es) * 2002-05-23 2005-03-07 Pfizer Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor.
DE60323133D1 (de) 2002-12-13 2008-10-02 Smithkline Beecham Corp Cyclohexylverbindungen als ccr5-antagonisten
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
CA2537185A1 (en) 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
ES2295924T3 (es) * 2003-10-03 2008-04-16 Pfizer, Inc. Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
BRPI0511982A (pt) 2004-06-09 2008-01-22 Hoffmann La Roche compostos antiviróticos heterocìclicos
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
EP2043640A2 (en) * 2006-06-12 2009-04-08 Pfizer Products Inc. Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
AU2007286345B2 (en) 2006-08-16 2012-03-08 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7932235B2 (en) 2006-11-17 2011-04-26 Concert Pharmaceuticals, Inc. Triazolyl tropane derivatives
JP5415957B2 (ja) 2006-12-13 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
EP2121676A1 (en) * 2006-12-19 2009-11-25 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8592395B2 (en) * 2009-07-24 2013-11-26 Glaxosmithkline Llc Therapeutic compounds
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
PL183025B1 (pl) * 1994-04-19 2002-05-31 Neurosearch As Pochodne tropanu, sposób ich otrzymywania i zawierające je kompozycje
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2000516210A (ja) * 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU8576098A (en) * 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
EP1047675A1 (en) * 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
JP3693957B2 (ja) * 2000-05-26 2005-09-14 ファイザー・インク 療法において有用なトロパン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
AU5248201A (en) 2001-12-03
NO20025227L (no) 2002-10-31
NL300338I2 (nl) 2008-06-02
TNSN01077A1 (fr) 2005-11-10
IS2511B (is) 2009-05-15
EP1990341B1 (en) 2013-01-23
KR100523501B1 (ko) 2005-10-25
EP1526134B1 (en) 2008-09-03
JP3693957B2 (ja) 2005-09-14
NO2010007I2 (no) 2013-09-09
IS6565A (is) 2002-09-24
ES2311126T3 (es) 2009-02-01
AU2001252482C1 (en) 2001-12-03
CA2408909A1 (en) 2001-11-29
NO327892B1 (no) 2009-10-12
OA12264A (en) 2003-11-10
MXPA02011631A (es) 2003-03-27
EP1526134A2 (en) 2005-04-27
JP2003534343A (ja) 2003-11-18
DE122008000011I1 (de) 2008-06-05
CN1680371A (zh) 2005-10-12
CY2022009I2 (el) 2022-05-27
HK1078573A1 (en) 2006-03-17
CY2008006I2 (el) 2009-11-04
HUP0302474A2 (hu) 2003-11-28
PT1284974E (pt) 2004-06-30
ME00555A (en) 2011-12-20
CN1437599A (zh) 2003-08-20
CR10145A (es) 2008-08-19
DK1526134T3 (da) 2008-11-17
NO20025227D0 (no) 2002-10-31
JP2005194283A (ja) 2005-07-21
WO2001090106A2 (en) 2001-11-29
EP1284974B1 (en) 2004-03-03
AP1965A (en) 2009-03-04
ME00555B (me) 2011-12-20
MY131019A (en) 2007-07-31
IL152531A (en) 2010-05-17
GEP20063799B (en) 2006-04-25
NZ521477A (en) 2004-07-30
BG65966B1 (bg) 2010-07-30
EA200401056A1 (ru) 2005-04-28
PE20011371A1 (es) 2002-01-18
FR08C0007I1 (enExample) 2008-04-25
KR100548854B1 (ko) 2006-02-02
LU91417I2 (fr) 2008-04-22
TR200400541T4 (tr) 2004-04-21
NO2010007I1 (no) 2010-04-08
MY153023A (en) 2014-12-31
LTC1284974I2 (lt) 2020-11-10
BR0110955A (pt) 2003-06-03
EP1990341A1 (en) 2008-11-12
HRP20020938A2 (en) 2005-02-28
SI1284974T1 (en) 2004-08-31
CU23288B7 (es) 2008-06-30
EP1526134A3 (en) 2006-11-29
SI1526134T1 (sl) 2008-12-31
WO2001090106A3 (en) 2002-03-28
HRP20020938B1 (en) 2011-05-31
UY26727A1 (es) 2001-12-28
DZ3464A1 (enExample) 2001-11-29
MA26902A1 (fr) 2004-12-20
EE200200656A (et) 2004-06-15
DE60102233T2 (de) 2005-01-27
BRPI0110955B1 (pt) 2016-06-28
FR08C0007I2 (fr) 2009-01-15
AR028622A1 (es) 2003-05-14
RS51436B (sr) 2011-04-30
EG24137A (en) 2008-08-06
ES2215129T3 (es) 2004-10-01
HU225810B1 (en) 2007-10-29
LU91417I9 (enExample) 2019-01-02
EP1284974A2 (en) 2003-02-26
RS50904B (sr) 2010-08-31
SK16432002A3 (sk) 2004-01-08
AP2002002663A0 (en) 2002-12-31
ATE260914T1 (de) 2004-03-15
CA2408909C (en) 2006-06-27
PA8517101A1 (es) 2002-10-24
EA007580B1 (ru) 2006-12-29
CN100355753C (zh) 2007-12-19
CZ20023806A3 (cs) 2004-01-14
HUP0302474A3 (en) 2007-05-29
HK1054927A1 (en) 2003-12-19
TWI230160B (en) 2005-04-01
EA005382B1 (ru) 2005-02-24
EE05110B1 (et) 2008-12-15
YU82202A (sh) 2005-11-28
DE60102233D1 (de) 2004-04-08
CY1108451T1 (el) 2014-04-09
ES2401812T3 (es) 2013-04-24
BRPI0110955B8 (pt) 2021-05-25
SK286129B6 (sk) 2008-04-07
MY156920A (en) 2016-04-15
PT1526134E (pt) 2008-10-28
NO2020019I1 (no) 2020-06-30
PL359267A1 (en) 2004-08-23
IL152531A0 (en) 2003-05-29
BG107140A (bg) 2003-05-30
CZ299102B6 (cs) 2008-04-23
AU2001252482B2 (en) 2006-01-19
KR20050046743A (ko) 2005-05-18
PL200551B1 (pl) 2009-01-30
DE60135685D1 (de) 2008-10-16
JP4854970B2 (ja) 2012-01-18
AR060159A2 (es) 2008-05-28
CY2008006I1 (el) 2009-11-04
RS20090438A (sr) 2010-05-07
CY2022009I1 (el) 2022-05-27
ATE407134T1 (de) 2008-09-15
HK1090836A1 (en) 2007-01-05
EA200201141A1 (ru) 2003-04-24
NL300338I1 (nl) 2008-05-01
DK1284974T3 (da) 2004-06-07
LTPA2008004I1 (lt) 2020-07-27
KR20030004417A (ko) 2003-01-14

Similar Documents

Publication Publication Date Title
CN1279040C (zh) 用于治疗的莨菪烷衍生物
CN1324025C (zh) 作为ccr5调节剂的托烷衍生物
CN1252071C (zh) 黄嘌呤磷酸二酯酶v抑制剂
CN1263755C (zh) 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
CN1291986C (zh) 抗胆碱能剂,其制备方法及其作为药物的用途
HK1039902A1 (zh) 用作趋化因子受体5调节剂的氮杂二环烷烃
CN1802159A (zh) 治疗哮喘及其它炎症或免疫性疾病的具有ccr3拮抗活性的2－苯氧基－和2－苯基磺酰胺衍生物
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
HK1039942A1 (en) Piperidines as ccr5 modulators
CN101068793A (zh) Hiv整合酶抑制剂的钾盐
CN1780621A (zh) 作为γ分泌酶抑制剂的磺酰胺衍生物
CN1659147A (zh) 哒嗪衍生物
CN1207731A (zh) 具有大麻素受体亲合力的3-吡唑甲酰胺衍生物
CN1433312A (zh) 作为治疗剂的巴比妥酸类似物
CN1922175A (zh) 作为5－ht4受体激动剂的吲唑－甲酰胺化合物
CN1826334A (zh) 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1812986A (zh) 呋咱并苯并咪唑类化合物
CN101048393A (zh) 作为γ－分泌酶抑制剂的取代的N－芳基磺酰基杂环胺
CN1875017A (zh) 取代的4－氨基－1－(吡啶基甲基)哌啶化合物的萘－1,5－二磺酸盐
CN1668614A (zh) 用作ccr1趋化因子受体拮抗剂双环哌啶衍生物
CN1703410A (zh) 异喹啉化合物及其医药用途
CN1620292A (zh) 含杂环取代苯基的磺酰胺广谱hiv蛋白酶抑制剂
CN1830445A (zh) 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物
CN1070859C (zh) 6-甲氧基-1h-苯并三唑-5-甲酰胺衍生物、其制造方法及含有该衍生物的医药组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20061011

CX01 Expiry of patent term